首药控股(688197) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was 0, representing a 100% decrease compared to the same period last year[5] - The net profit attributable to shareholders was -35,084,820.25 RMB, with a cumulative net profit of -119,160,116.84 RMB for the year, indicating significant losses[5] - Net profit for Q3 2022 was -119,160,116.84 RMB, compared to -103,916,069.53 RMB in Q3 2021, reflecting a decline of approximately 14.5% year-over-year[38] - Total operating profit for Q3 2022 was -119,167,137.81 RMB, compared to -104,540,066.53 RMB in Q3 2021, indicating a worsening of approximately 14%[34] - The total comprehensive income for Q3 2022 was -119,160,116.84 RMB, compared to -103,916,069.53 RMB in Q3 2021, indicating a decline of approximately 14.5%[38] - The total profit (loss) for the period was -118,530,166.43 RMB, compared to -107,772,468.52 RMB in the previous period[58] Research and Development - Research and development expenses totaled 44,369,492.95 RMB for the quarter, which is an increase of 4.93% year-on-year, and 138,861,411.72 RMB for the year-to-date, up 28.69%[9] - The ratio of R&D expenses to operating revenue for the year-to-date reached 7,778.40%, an increase of 6,797.48 percentage points due to decreased revenue and increased R&D investment[9] - Research and development expenses increased to 138,861,411.72 RMB in Q3 2022, up from 107,900,743.84 RMB in Q3 2021, representing a growth of about 28.7%[34] - Research and development expenses rose to 144,736,976.18, up from 113,428,896.24, highlighting the company's commitment to innovation[56] Assets and Liabilities - Total assets at the end of the reporting period were 1,354,934,334.44 RMB, reflecting a 2,229.03% increase compared to the end of the previous year[9] - As of September 30, 2022, the company's total assets amounted to RMB 1,354,934,334.44, a significant increase from RMB 58,175,956.99 at the end of 2021[26][31] - The company’s total liabilities reached RMB 93,753,810.95, compared to RMB 56,674,242.87 at the end of 2021, reflecting increased operational scale[31] - The total liabilities amounted to 94,463,368.71, an increase from 60,018,128.91, indicating a rise in the company's obligations[52] Equity and Shareholder Information - Shareholders' equity attributable to the parent company was 1,261,180,523.49 RMB, showing an increase of 83,882.73% due to the influx of funds from the IPO[9] - The total number of ordinary shareholders at the end of the reporting period was 13,903, with the largest shareholder holding 49.05% of the shares[17] - The company’s total equity reached 1,261,843,259.66, reflecting a decrease from the previous total[54] Cash Flow and Financing Activities - Cash inflow from operating activities for the first nine months of 2022 was 57,348,197.80 RMB, significantly higher than 23,014,081.49 RMB in the same period of 2021, marking an increase of about 149%[42] - The company reported a net cash flow from operating activities of -86,784,273.21, compared to -85,871,457.76 in the previous period, indicating a slight increase in cash outflow[45] - Cash inflow from financing activities totaled 1,408,529,683.77 RMB, with a net cash flow from financing activities of 1,379,271,583.77 RMB[64] - The company received 15,000,000.00 RMB in cash from loans during the financing activities[63] Inventory and Operational Costs - The company reported a significant increase in inventory, which rose to RMB 2,570,195.58 from RMB 1,462,705.60 in the previous year[26] - The total operating costs for the first three quarters of 2022 were RMB 141,671,074.06, up from RMB 123,833,942.07 in the previous year[31] Other Income and Expenses - The company received government subsidies amounting to 8,243,115.60 RMB during the quarter, contributing to its non-operating income[11] - Other income increased to 19,717,707.40 RMB in Q3 2022, compared to 8,328,122.40 RMB in Q3 2021, reflecting a growth of about 137%[34] - Interest income rose significantly to 13,993,277.51 RMB in Q3 2022, compared to 1,357,329.80 RMB in Q3 2021, an increase of over 930%[34] - Management expenses decreased to 16,463,068.15 RMB in Q3 2022 from 17,065,775.99 RMB in Q3 2021, a reduction of approximately 3.5%[34]